The way we develop new drugs is broken. The process costs too much, takes too long, and far too often it simply doesn't work. I sat down with five leaders in the field—from industry, VC, academia, and government—to hear their takes on how, and why, and what we can do about it.

SF is plausibly the only place you can fill a room for the live screening of a podcast about clinical trial process improvement

For the first episode of Development & Research, I spoke with Meri Beckwith on: • being a patient in an incompetently-run clinical trial, • how many drug trials fail b/c of bad paperwork, • who benefits when trials are expensive, • just how quickly biotech founders lose

We're back with Development & Research, where I spoke with Brian Finrow on: • why we should grow more drugs in algae, and fewer in Chinese Hamster Ovary cells, • why "monoclonal antibodies" are particularly safe and effective as drugs—but incredibly expensive to manufacture, • and whether

This week on Development & Research, I sat down with Charlie Petty to talk about: • are there profitable investments in global public health? (and are there hundreds of millions of dollars of them?) • what makes investing in public health is harder (and easier) than conventional

This week on Development & Research I'm chatting with Jessica Sacher, PhD, who has spent more than a decade studying natural viruses that kill bacteria. Oh, and she personally prepared experimental treatments that cured a dozen patients' chronic bacterial infections after all known

For the final episode of Season 1 of Development & Research, I'm sitting down with Ambassador Mark Dybul—one of the architects of the President's Emergency Plan for AIDS Relief—who argues that America has forgotten the core insight of the Marshall Plan: supporting other countries'